A number of other brokerages also recently issued reports on EVOK. Zacks Investment Research upgraded shares of Evoke Pharma from a “sell” rating to a “hold” rating in a report on Tuesday. HC Wainwright reaffirmed a “hold” rating on shares of Evoke Pharma in a research report on Friday, June 28th.
EVOK stock traded down $0.02 during mid-day trading on Thursday, reaching $0.90. The company’s stock had a trading volume of 236,095 shares, compared to its average volume of 1,779,490. The stock has a market cap of $20.94 million, a PE ratio of -1.96 and a beta of 1.61. Evoke Pharma has a fifty-two week low of $0.50 and a fifty-two week high of $3.40. The company’s 50 day moving average price is $0.82.
Large investors have recently bought and sold shares of the stock. Virtu Financial LLC purchased a new position in shares of Evoke Pharma during the 1st quarter worth approximately $118,000. Marshall Wace LLP purchased a new position in shares of Evoke Pharma during the 1st quarter worth approximately $139,000. Finally, BlackRock Inc. boosted its position in shares of Evoke Pharma by 5.5% during the 4th quarter. BlackRock Inc. now owns 83,583 shares of the specialty pharmaceutical company’s stock worth $207,000 after purchasing an additional 4,392 shares during the period. 7.40% of the stock is owned by hedge funds and other institutional investors.
About Evoke Pharma
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
Featured Story: Price to Earnings Ratio (PE)
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.